Clinical and Treatment Determinant of Prognosis in Glioblastoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Glioblastoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Gliomas represent the most common primary malignant brain tumors in adults, with glioblastoma (WHO grade 4) being the most aggressive subtype. Despite advances in surgical techniques, radiotherapy, and chemotherapy, prognosis remains poor, particularly for high-grade gliomas. Maximal safe surgical resection is considered a cornerstone in the management of gliomas. Several studies suggest that a greater extent of resection (EOR) is associated with improved overall survival (OS) and progression-free survival (PFS), particularly in high-grade tumors. However, the benefit must be balanced against the risk of neurological deficits. Postoperative chemoradiotherapy, particularly with temozolomide, has become the standard of care for high-grade gliomas. Despite this, the impact of EOR on outcomes in the context of adjuvant chemoradiotherapy remains a subject of ongoing investigation. This study aims to evaluate the prognostic significance of the extent of surgical resection in glioma patients who undergo postoperative chemoradiotherapy.
Primary outcome measures
- Overall survival [Time frame: 5 years]
Eligibility criteria
Inclusion criteria
- Adult patients (≥18 years) with histologically confirmed glioma (WHO grades 2-4) Underwent neurosurgical resection (gross total, subtotal, or biopsy only) Received postoperative radiotherapy with or without concurrent and/or adjuvant temozolomide Available pre- and post-operative imaging for EOR assessment Complete medical records and follow-up data
Exclusion criteria
- Recurrent gliomas at presentation Incomplete treatment (e.g., abandonment, death before adjuvant therapy) Lack of imaging or follow-up data
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07197086 · glioblastoma clinical &treat